This is a Phase 1, single-site, open label, exploratory study to assess delivery of LMN-201 components via enteric capsules in the gut of individuals with ostomies.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
12
Components of LMN-201
Components of LMN-201
Components of LMN-201
Wesley Medical Research Limited
Auchenflower, Queensland, Australia
Coastal Digestive Health
Maroochydore, Queensland, Australia
Coral Sea Clinical Research Institute
North Mackay, Queensland, Australia
Number of Participants With Presence of Capsules and/or Transit Markers in Ostomy Fluid by Visual Observation
Count of participants with the presence or absence of capsules and/or transit markers at each collection timepoint in ostomy fluid by visual observation.
Time frame: Arrival (baseline), Predose (immediately before dosing), and up to 12 hours post dose.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Components of LMN-201